Journal article

Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis

Stella G Muthuri, Sudhir Venkatesan, Puja R Myles, Jo Leonardi-Bee, Wei Shen Lim, Abdullah Al Mamun, Ashish P Anovadiya, Wildo N Araujo, Eduardo Azziz-Baumgartner, Clarisa Baez, Carlos Bantar, Mazen M Barhoush, Matteo Bassetti, Bojana Beovic, Roland Bingisser, Isabelle Bonmarin, Victor H Borja-Aburto, Bin Cao, Jordi Carratala, Maria R Cuezzo Show all

Influenza and Other Respiratory Viruses | WILEY | Published : 2016


BACKGROUND: The impact of neuraminidase inhibitors (NAIs) on influenza-related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1)pdm09 virus infection. METHODS: A worldwide meta-analysis of individual participant data from 20 634 hospitalised patients with laboratory-confirmed A(H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) 'pandemic influenza'. The primary outcome was radiologically confirmed IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids. RESULTS: Of 20..

View full abstract

University of Melbourne Researchers


Awarded by National Institute for Health Research

Funding Acknowledgements

The PRIDE study is funded via an unrestricted educational grant from F. Hoffmann-La Roche, Switzerland [the manufacturers of Oseltamivir (Tamiflu (R))]. The funder has had no role in protocol design, no opportunity to comment on it and no opportunity to see it other than via the PROSPERO website; no access to any data (and no rights to future access); no role in analysis or interpretation; no opportunity to preview results/findings before entry into the public domain; no opportunity to contribute to, preview or comment on manuscripts and presentations arising from this work. The research contract between the University of Nottingham and the funder is freely available for inspection (commercial details redacted) at: